[Activity of sodium-lithium cotransport in erythrocytes of patients with diabetes mellitus type I (IDDM) complicated by diabetic nephropathy in the renal failure stage].
Sodium-lithium countertransport (SLC) in erythrocytes represents one of the transmembrane sodium transport systems. SLC activity is elevated in arterial hypertension, diabetes mellitus type I (IDDM) complicated with nephropathy, hyperlipidemia, hyperuricemia and pregnancy. Increase of SLC is considered as a genetic marker of primary arterial hypertension. In present paper SLC was assessed in 12 patients with IDDM without nephropathy (group I), 12 patients with IDDM complicated with diabetic nephropathy on hemodialytic treatment (group II), 15 patients treated with haemodialysis due to non-diabetic nephropathy (group III) and 12 healthy subjects (group IV). All groups were matched in respect of age. Serum creatinine concentration and inulin clearance were similar in groups I and IV as well as in groups II and III. SLC was assessed according to method described by Canessa and coworkers (1980). SLC activity in group II (0.60 mmol/l litre of erythrocytes/h; 0.43-0.94; 0.28-1.22) (median, 25%-75%, min.-max.) was significantly higher than in other groups-group I (0.30; 0.20-0.38; 0.12-0.57), group III (0.24; 0.16-0.33; 0.11-0.38) and group IV (0.20; 0.15-0.25; 0.12-0.27). In 3 patients of group I the values were higher than in all examined of groups III and IV and approximated to mean values of group II. The results confirm a significant rise of SLC activity in patients with IDDM complicated with end-stage diabetic nephropathy. SLC activity in end-stage renal disease due to non-diabetic nephropathy does not differ from values in healthy subjects. It seems that elevated SLC activity in IDDM might be a genetic marker foretelling development of nephropathy.
Trelewicz
P
P
Oddziału Wewnetrznego IV Specjalistycznego Szpitala Miejskiego Stalownik w Bielsku-Białej.
Gumprecht
J
J
Zukowska-Szczechowska
E
E
Grzeszczak
W
W
Moczulski
D
D
Liszka
M
M
D000328:Adult; D017920:Antiporters / Q000097:blood*; D003922:Diabetes Mellitus, Type 1 / Q000097:blood*; D003928:Diabetic Nephropathies / Q000097:blood*; D004912:Erythrocytes / Q000378:metabolism*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood*; D008094:Lithium / Q000097:blood*; D008875:Middle Aged; D012964:Sodium / Q000097:blood*
D017920:Antiporters; D008094:Lithium; D012964:Sodium